Canary Bio Recruits Robert Heojin, Who Led Orinia to Success

[Asia Economy Reporter Jang Hyowon] Canaria Bio (CEO Nahanik) announced on the 19th that it has recruited Robert Huizinga, who developed a treatment substance for lupus nephritis at Orinia Pharmaceutical and obtained approval from the U.S. Food and Drug Administration (FDA), as the head of the new drug development division.

CEO Nahanik stated, “Robert Huizinga already has experience obtaining FDA approval,” and explained the reason for the recruitment, saying, “We have scouted a new drug development expert with successful DNA, keeping in mind the FDA approval of Oregovomab.”

Orinia obtained FDA product approval for voclosporin last year. It is also well known in the Korean market as a company in which the Korean Iljin Group invested and earned profits exceeding 100 billion KRW. Additionally, Orinia, like OncoQuest which sold Oregovomab to Canaria Bio, is a company that started in Edmonton, Canada.

Robert Huizinga, head of the new drug development division, led the entire process from preclinical stages to clinical trials and FDA approval at Orinia for the past 20 years, successfully bringing 30 years of new drug development experience to Canaria Bio.

Robert Huizinga said, “Oregovomab, like Orinia’s voclosporin, started in Edmonton, Canada and is being developed with Korean capital,” adding, “Just as voclosporin was successful, I will do my best to ensure Oregovomab’s success and respond to the trust given by shareholders, patients, and medical staff.”

This content was produced with the assistance of AI translation services.